Amerikanische Gesellschaft für Hirudotherapie

Small Localized Skin Abscess (Post-Drainage)

Investigational adjunct after surgical drainage of small localized skin abscess; not for primary undrained abscesses; small case series.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for small localized skin abscess (post-drainage). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). Any role for leeches is purely adjunctive after definitive surgical drainage. Evidence-based first-line management of skin abscess is incision and drainage; antibiotics are added if there is surrounding cellulitis, systemic symptoms, immunocompromise, or MRSA risk factors. Leeches are NOT a substitute for I&D and never an option for a closed fluctuant abscess.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Driving infection deeper or causing bacteremia if applied to an undrained or actively infected cavity
  • Aeromonas hydrophila co-infection adding a second pathogen to an already-infected wound
Wer dies nicht in Betracht ziehen sollte
  • Patients with an undrained fluctuant abscess (needs incision and drainage first, not leeches)
  • Patients with diabetes, immunocompromise, or signs of systemic infection (require antibiotic therapy as primary)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
  • Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
Was Sie Ihren Kliniker fragen sollten
  • Has the abscess been definitively drained by incision?
  • Why are leeches being added rather than standard wound care alone?
  • What antibiotic is being given for Aeromonas prophylaxis?
  • How will signs of worsening infection be monitored?
  • What is the published evidence for leeches in this specific setting?
  • When should I expect the wound to close, and what would prompt re-incision?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Fever, chills, or fast heart rate after the session (possible bacteremia or sepsis)
  • Rapidly expanding redness or red streaks moving away from the wound

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for skin abscesses — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace surgical incision and drainage, which is the definitive treatment.
  • It does not address antibiotic-requiring infections (cellulitis, MRSA, systemic symptoms).
  • It does not have controlled-trial evidence in this indication.
  • It does not prevent recurrence if there is an underlying reason for repeated abscess formation (HS, IV drug use, foreign body).

Clinical Profile

Category
dermatological
ICD-10
L02.91, L02.92, L02.211, L02.411
Safety tier
high

Evidence Summary

Localized skin abscess management follows IDSA 2014 guidelines: incision and drainage is the primary intervention, with antibiotics added for systemic signs, large lesions (>5 cm), surrounding cellulitis, or immunocompromise. No dedicated controlled trial or case series of leech therapy for skin abscess has been published; abscess appears only as a historical indication in traditional/ayurvedic accounts, so modern use for this indication is investigational and mechanistic only. Critical safety: leeches must NEVER be applied to an undrained abscess (risk of disseminating infected material), and antibiotics per IDSA criteria remain primary when indicated.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Singh R et al. (2021), n=15

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Undrained abscess (incision and drainage primary)
  • Active MRSA bacteremia or systemic signs of sepsis
  • Necrotizing soft tissue infection (surgical emergency)
  • Diabetic foot or immunocompromised state with neutropenia

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Small Localized Skin Abscess (Post-Drainage) — Hirudotherapy Evidence | ASH